Research confirms that VEGF and VEGFR are key regulators in lung cancer angiogenesis, serving as primary therapeutic targets for antivascular drug development to inhibit tumor growth, metastasis, and drug resistance. This evidence concerns the gene VEGFA and lung carcinoma.